AEON Biopharma, Inc. (NYSE: AEON) shares fell slightly Wednesday. The Aliso Viejo, Calif.-based company, a biopharmaceutical concern advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced final, expanded primary structure results and preliminary disulfide bond characterization data that provide complementary evidence supporting the molecular similarity of ABP-450 to BOTOX®.
The expanded primary structure analysis achieved 98% sequence coverage of the active botulinum neurotoxin and demonstrated 100% amino acid identity across every region analyzed. Preliminary disulfide characterization identified the same C430-C454 bond connecting the light and heavy chains in both products across all tested lots.
“Primary structure is the molecular blueprint of a protein, and disulfide connectivity helps confirm that critical regions of the molecule are covalently linked in the same manner,” said CEO Rob Bancroft.
“Achieving 98% sequence coverage with complete identity across all analyzed regions, together with preliminary evidence of the same dominant heavy-chain/light-chain disulfide bond in both products, represents meaningful progress in building the foundational molecular identity package for ABP-450. The consistency of these findings across multiple samples and lots increases our confidence as we continue to build the broader analytical evidence supporting the program.”
AEON shares declined 0.3 cents, or 1.1%, to 24 cents.
Related Stories
